Tscan Therapeutics is trading lower at $0.34 (-13.26%) on September 8, 2026, following downgrades by analysts including H.C. Wainwright and Wedbush. * This comes after the company's September 2 strategic reorganization, which prioritized preclinical solid-tumor programs and paused further enrollment in the Phase 3 ALLOHA-2 study due to capital constraints. * The reorganization also includes an approximately 75% workforce reduction, with executive departures, and is expected to generate $55 million in cumulative cost savings through 2027.